MorphoSys AG (MOR): Price and Financial Metrics

MorphoSys AG (MOR): $5.01

0.18 (+3.73%)

POWR Rating

Component Grades














  • Growth is the dimension where MOR ranks best; there it ranks ahead of 76.76% of US stocks.
  • The strongest trend for MOR is in Quality, which has been heading down over the past 179 days.
  • MOR ranks lowest in Momentum; there it ranks in the 4th percentile.

MOR Stock Summary

  • With a year-over-year growth in debt of 121.68%, MorphoSys AG's debt growth rate surpasses 91.42% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, MorphoSys AG is reporting a growth rate of 211.14%; that's higher than 90.17% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MOR comes in at -136.97% -- higher than that of only 2.6% of stocks in our set.
  • Stocks that are quantitatively similar to MOR, based on their financial statements, market capitalization, and price volatility, are RBBN, FF, MESO, KGC, and THTX.
  • MOR's SEC filings can be seen here. And to visit MorphoSys AG's official web site, go to

MOR Valuation Summary

  • In comparison to the median Healthcare stock, MOR's price/sales ratio is 250% higher, now standing at 13.3.
  • Over the past 41 months, MOR's price/sales ratio has gone down 32.3.
  • MOR's EV/EBIT ratio has moved up 2.7 over the prior 41 months.

Below are key valuation metrics over time for MOR.

Stock Date P/S P/B P/E EV/EBIT
MOR 2021-08-31 13.3 3.2 -18.6 -41.7
MOR 2021-08-30 12.5 3.0 -17.5 -39.8
MOR 2021-08-27 13.2 3.2 -18.5 -41.5
MOR 2021-08-26 12.9 3.1 -18.0 -40.7
MOR 2021-08-25 13.0 3.1 -18.2 -41.0
MOR 2021-08-24 13.3 3.2 -18.5 -41.6

MOR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MOR has a Quality Grade of C, ranking ahead of 47.08% of graded US stocks.
  • MOR's asset turnover comes in at 0.092 -- ranking 273rd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MOR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.092 0.803 -0.030
2021-03-31 0.081 0.911 -0.063
2021-03-31 0.081 0.911 -0.063
2020-12-31 0.226 0.972 0.070
2020-09-30 0.261 0.997 0.085
2020-06-30 0.309 1.006 0.117

MOR Stock Price Chart Interactive Chart >

Price chart for MOR

MOR Price/Volume Stats

Current price $5.01 52-week high $19.83
Prev. close $4.83 52-week low $4.35
Day low $4.86 Volume 17,500
Day high $5.05 Avg. volume 69,728
50-day MA $5.17 Dividend yield N/A
200-day MA $8.09 Market Cap 686.01M

MorphoSys AG (MOR) Company Bio

MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.

MOR Latest News Stream

Event/Time News Detail
Loading, please wait...

MOR Latest Social Stream

Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MorphoSys AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

LinkinVax Raises $4.35M in Seed Funding

LinkinVax, a Paris, France-based clinical-stage biotechnology company, raised $4.35M in Seed funding. Backers included André- Jacques Auberton- Hervé (co-founder and CEO of LinKinVax), Jean-Paul Kress (CEO of Morphosys), Geoffrey Duyk (US biotechnology entrepreneur and investor), Giorgio Anania, Rémi Gaston- Dreyfus and Alain Tingaud (recognized entrepreneurs in the high-tech sector).The company intends to use the funds [] The post LinkinVax Raises $4.35M in Seed Funding appeared first on FinSMEs .

FinSMEs | February 11, 2022

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Investment Thesis Sierra Oncology (SRRA) bucked the nightmarish biotech bear trend this week. Its shares leapt by 48%, to a price of $26.5 at the time of writing after the company announced unexpectedly positive results from a pivotal Phase 3 trial of its lead candidate, the oral JAK inhibitor Momelotinib...

Edmund Ingham on Seeking Alpha | January 28, 2022

Sierra Oncology''s Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

No summary available.

Seeking Alpha | January 28, 2022

MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among European healthcare companies for female representation at the leadership level and in decision-making positions.The European Women on Boards Gender Equality Index Report assessed 668 European companies across 19 countries, predominately coming from

Yahoo | January 24, 2022

MorphoSys dips 2% after providing 2022 guidance

MorphoSys AG <> provides preliminary net product sales for the full year of 2021 and guidance for 2022.Monjuvi

Seeking Alpha | January 18, 2022

Read More 'MOR' Stories Here

MOR Price Returns

1-mo -8.33%
3-mo -28.43%
6-mo -48.51%
1-year -73.58%
3-year -79.58%
5-year N/A
YTD -46.82%
2021 -66.76%
2020 -20.55%
2019 40.99%
2018 N/A
2017 N/A

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6148 seconds.